LBPH insider transaction filings
Longboard Pharmaceuticals, Inc. — 22 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-12-02. Screen LBPH transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for LBPH between 2026-06-11 and 2026-09-09. The table below lists the most recent filings on record.
Recent Form 4 filings — Longboard Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-12-02 | 4 | Le Goff Corinne — Director | Disposition to issuer (D): 12,367 (derivative) · Disposition to issuer (D): 13,397 (derivative) · Disposition to issuer (D): 12,367 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) | EDGAR |
| 2024-12-02 | 4 | Lynch Casey — Director | Disposition to issuer (D): 12,367 (derivative) · Disposition to issuer (D): 14,428 (derivative) · Disposition to issuer (D): 12,367 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) | EDGAR |
| 2024-12-02 | 4 | Lind Kevin Robert — President and CEO, Director | Code (U): 363,740 @ $60 · Disposition to issuer (D): 255,377 (derivative) · Disposition to issuer (D): 192,783 (derivative) · Disposition to issuer (D): 325,850 (derivative) · Disposition to issuer (D): 332,134 (derivative) · Disposition to issuer (D): 22,000 (derivative) | EDGAR |
| 2024-12-02 | 4 | Aurentz Vincent — Director | Disposition to issuer (D): 12,367 (derivative) · Disposition to issuer (D): 7,214 (derivative) · Disposition to issuer (D): 12,367 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) | EDGAR |
| 2024-12-02 | 4 | Roberts Brandi — Executive VP and CFO | Disposition to issuer (D): 139,380 (derivative) · Disposition to issuer (D): 90,000 (derivative) · Disposition to issuer (D): 119,700 (derivative) · Disposition to issuer (D): 90,580 (derivative) · Disposition to issuer (D): 15,090 (derivative) · Disposition to issuer (D): 7,900 (derivative) | EDGAR |
| 2024-12-02 | 4 | Kaye Randall — Executive Vice President & CMO | Code (U): 30,554 @ $60 · Disposition to issuer (D): 175,946 (derivative) · Disposition to issuer (D): 96,300 (derivative) · Disposition to issuer (D): 107,560 (derivative) · Disposition to issuer (D): 17,920 (derivative) · Disposition to issuer (D): 9,500 (derivative) | EDGAR |
| 2024-12-02 | 4 | SEKHRI PAUL J — Director | Disposition to issuer (D): 25,461 (derivative) · Disposition to issuer (D): 12,367 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) | EDGAR |
| 2024-12-02 | 4 | SCHNEIDER PHILLIP M — Director | Disposition to issuer (D): 25,461 (derivative) · Disposition to issuer (D): 12,367 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) | EDGAR |
| 2024-11-19 | 4 | Kaye Randall — CMO | Option exercise (M): 30,554 @ $6 · Option exercise (M): 30,554 (derivative) @ $0 | EDGAR |
| 2024-11-13 | 4 | Lind Kevin Robert — CEO, Director | Option exercise (M): 12,808 @ $3.12 · Gift (G): 80,000 @ $0 · Option exercise (M): 12,808 (derivative) @ $0 | EDGAR |
| 2024-10-29 | 4 | Lind Kevin Robert — CEO, Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2024-10-29 | 4 | Roberts Brandi — CFO | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2024-10-29 | 4 | Kaye Randall — CMO | Grant/award (A): 9,500 (derivative) @ $0 | EDGAR |
| 2024-10-16 | 4 | Kaye Randall — CMO | Option exercise (M): 16,667 @ $4.35 · Sale (S): 16,667 @ $59.03 · Option exercise (M): 16,667 (derivative) @ $0 | EDGAR |
| 2024-09-16 | 4 | Kaye Randall — CMO | Option exercise (M): 16,666 @ $4.35 · Sale (S): 9,366 @ $30.89 · Sale (S): 4,200 @ $31.81 · Sale (S): 1,200 @ $33.12 · Sale (S): 1,900 @ $34.04 · Option exercise (M): 16,666 (derivative) @ $0 | EDGAR |
| 2024-08-13 | 4 | Lind Kevin Robert — CEO, Director | Option exercise (M): 80,265 @ $3.12 · Option exercise (M): 2,217 @ $4.20 · Option exercise (M): 80,265 (derivative) @ $0 · Option exercise (M): 2,217 (derivative) @ $0 | EDGAR |
| 2024-08-13 | 4 | Kaye Randall — CMO | Purchase (P): 100 @ $24.82 · Sale (S): 100 @ $20.87 · Option exercise (M): 16,667 @ $4.35 · Sale (S): 10,476 @ $34.55 · Sale (S): 6,191 @ $35.03 · Option exercise (M): 16,667 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Le Goff Corinne — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Lynch Casey — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Aurentz Vincent — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | SEKHRI PAUL J — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | SCHNEIDER PHILLIP M — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Longboard Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-12-02 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-01 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-07-01 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-24 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LBPH returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →